Iridoids: Research Advances in Their Phytochemistry, Biological Activities, and Pharmacokinetics

Congcong Wang 1, Xue Gong 1, Agula Bo 1, Lei Zhang 2, Mingxu Zhang 1, Erhuan Zang 1, Chunhong Zhang 1,3,* and Minhui Li 1,4,*

1 Baotou Medical College, Baotou 014060, Inner Mongolia, China; WangCongCong0@163.com (C.W.); gongxue_2017@yeah.net (X.G.); agula372000@126.com (A.B.); zhang_mingxu@yeah.net (M.Z.); huan15733941992@163.com (E.Z.)
2 Faculty of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, Inner Mongolia, China; 15771378662@163.com
3 Inner Mongolia Key Laboratory of Traditional Chinese Medicine Resources, Baotou Medical College, Baotou 014060, Inner Mongolia, China
4 Inner Mongolia Institute of Traditional Chinese Medicine, Hohhot 010020, Inner Mongolia, China
* Correspondence: zchlhh@126.com (C.Z.); prof_liminhui@yeah.net (M.L.); Tel.: +86-472-716-6531 (C.Z.); +86-472-716-7795 (M.L.)

Academic Editor: Derek J. McPhee
Received: 27 November 2019; Accepted: 8 January 2020; Published: 10 January 2020

Abstract: Iridoids are a class of active compounds that widely exist in the plant kingdom. In recent years, with advances in phytochemical research, many compounds with novel structure and outstanding activity have been identified. Iridoid compounds have been confirmed to mainly exist as the prototype and aglycone and I and II metabolites, by biological transformation. These metabolites have been shown to have neuroprotective, hepatoprotective, anti-inflammatory, antitumor, hypoglycemic, and hypolipidemic activities. This review summarizes the new structures and activities of iridoids identified locally and globally, and explains their pharmacokinetics from the aspects of absorption, distribution, metabolism, and excretion according to the differences in their structures, thus providing a theoretical basis for further rational development and utilization of iridoids and their metabolites.

Keywords: iridoids; phytochemistry; biological activities; pharmacokinetics

1. Introduction

Iridoids, a large and still expanding class of cyclopentane pyran monoterpenes, are composed of two basic carbon frameworks, substituted iridoids, and secoiridoids. They are more prevalent in the kingdom Plantae, especially in the dicotyledonous plants from Scrophulariaceae, Pyrolaceae, Oleaceae, Labiatae, Rubiaceae, and Gentianaceae [1,2]. Based on the structure, these compounds can be divided into four groups: iridoid glycosides, secoiridoid glycosides, non-glycosidic iridoids, and bis-iridoids. Iridoids have hemiacetal hydroxyl groups and are active in nature. Besides, they are mostly in the form of glycosides and are combined with glucose at the C-1 hydroxyl group [3,4]. Most glycosides share similar properties such as strong modifiability and rapid absorption; hence, they are popular sources of lead compounds. Their prominent effects in various diseases have shown their importance in pharmaceutical chemistry research. As one of the active components used in natural medicine and traditional Chinese medicine, iridoid compounds have many biological effects such as liver protection, anti-inflammatory and anti-tumor effects [5–7]. However, in recent years, there has been no systematic arrangement and summary of iridoids. This review paper aims to characterize iridoids based on their phytochemistry, biological activities, and pharmacokinetics, through the analysis and comparative
study of the structure and function of known iridoids. The characterization will provide a framework for new medicine development and research, enabling the exploration of the remarkable medicinal potential of these compounds.

The systematic summary in this paper was produced by searching for relevant information about iridoids on websites such as Google Scholar, PubMed, CNKI, Baidu Scholar, SciFinder Scholar, TPL (www.theplantlist.org), and Web of Science. The following words and/or phrases were used in various combinations, “iridoids”, “iridoids phytochemistry”, “iridoids classification”, “iridoid glycosides”, “secoiridoid glycosides”, “bis-iridoids”, “non-glycosidic iridoids”, “iridoids activities”, “iridoids pharmacological”, “iridoids pharmacokinetic”. More than 100 scientific works of literature were consulted from 2009 to 2019.

2. Phytochemistry

Iridoids belong to monoterpenoids, which are acetal derivatives of iridodial [8]. Because of the unstable nature of its C1-OH group, iridoids often react with sugar to form glycosides. According to the integrity of the cyclopentane unit, it can be divided into two types: iridoid glycosides (including geniposide, loganin, acetylbarlerin, deacetylasperulosidic acid, and brasoside) and secoiridoid glycosides (including swertiamarine, gentiopicroside, qinjiaoside A, qinjiaoside B, sweroside, and oleuropein). In addition, the dimer of iridoids called as bis-iridoids (including cantleyoside, laciniatoside I-II, and sylvestroside I) and unglycosylated iridoids called as non-glycosidic iridoids (including acevaltrate and valtrate) [9,10] are also found in nature. Compounds with such structures possess a variety of physiological activities and are used as sedating and antipyretic agents [8,11]. Tundis et al. have detailed summaries of active compounds prior to 2008 [12], Table 1 lists the active iridoids from 2009 to 2019 in the last 11 years. Three basic skeletons of iridoids are elucidated in Figure 1.

![Figure 1. Three basic skeletons of iridoids.](image)

| No. | Classes                  | Compounds                                      | Sources                        | Ref.   |
|-----|--------------------------|------------------------------------------------|--------------------------------|--------|
| 1   | Iridoid glycosides       | Euphoside                                      | Scrophulariaceae               | [13]   |
| 2   |                         | Plantarenaloside                               | Plantaginaceae, Bignoniaceae   | [14,15]|
| 3   |                         | Geniposidic acid                              | Scrophulariaceae, Labiatae     | [13]   |
| 4   | Loganic acid             |                                                 | Acanthaceae                    | [16]   |
| 5   | Loganic acid-6'-O-(α-D-glucoside) |                                          | Gentianaceae                    | [17]   |
| 6   | 2'-O-(4-methoxycinnamoyl) mussiaenosidic acid |                                         | Acanthaceae                    | [18]   |
| 7   | 2'-O-trans-coumaroylshanzhiside |                                         | Rubiaceae                      | [19]   |
| 8   | 6'-O-trans-coumaranoyl-shanzhiside |                                         | Rubiaceae                      | [19]   |
| 9   | Mussiaenoside            |                                                 | Scrophulariaceae               | [13]   |
| 10  | Lupulinoside             |                                                 | Acanthaceae                    | [20]   |
| 11  | 8-epideoxyloganic acid   |                                                 | Bignoniaceae                    | [14]   |
| 12  | Shanzhiside methyl ester |                                                 | Acanthaceae                    | [20]   |
| 13  | Barlerin                 |                                                 | Acanthaceae                    | [20]   |
| 14  | Acetylbarlerin           |                                                 | Acanthaceae                    | [20]   |
| 15  | 6-O-trans-p-coumaroyl-8-O-acetylsanzhi side methyl ester |                                         | Acanthaceae                    | [20]   |
| 16  | 6'-O-acetylgeniposide    |                                                 | Rubiaceae                      | [21]   |
| 17  | 6'-O-trans-p-coumaroylgeniposide |                                         | Rubiaceae                      | [21]   |
| No. | Classes | Compounds | Sources | Ref. |
|-----|---------|-----------|---------|------|
| 18  | 6′-O-trans-p-coumaroyl-geniposidic acid | Rubiaceae | [21] |
| 19  | 6′-O-trans-sinaparylenigenoside | Rubiaceae | [21] |
| 20  | Pinnotoside | Verbenaceae | [22] |
| 21  | 6β-ethoxygeniposide | Rubiaceae | [19] |
| 22  | 10-O-acetylenigenoside | Rubiaceae | [21] |
| 23  | Eurostoside | Scrophulariaceae | [23] |
| 24  | 10-O-succinoxygeniposide | Rubiaceae | [21] |
| 25  | Nimpigenin | Scrophulariaceae | [24] |
| 26  | 8-O-(coumaroyl)harpagide | Scrophulariaceae | [24] |
| 27  | 6-O-α-ν-galactopyranosylharpagside | Scrophulariaceae | [24] |
| 28  | 8-Overoylharpagide | Scrophulariaceae | [24] |
| 29  | Dihydropenstemide | Plantaginaceae | [15] |
| 30  | Patentilloside A | Valerianaceae | [25] |
| 31  | 10-isovaleroyl-dihydropenstemide | Loganiaceae | [26] |
| 32  | Buddlejoside A9 | Loganiaceae | [26] |
| 33  | 6-O-α-L-(′-acetyl-4′-O-trans-isoferuloyl) | Loganiaceae | [26] |
| 34  | 6-O-α-L-(4′-O-trans-cinnamoyl) | Loganiaceae | [26] |
| 35  | 6-O-α-ν-glucopyranosyl gentiopicroside | Gentianaceae | [34] |
| 36  | Oleoside dimethyl ester | Oleaceae | [35] |
| 37  | (8E)-nuezhenide | Oleaceae | [35] |
| 38  | (8Z)-nuezhenide | Oleaceae | [35] |
| 39  | 7-hydroxy eucommiol | Acanthaceae | [20] |
| 40  | 7-methoxydiereroside | Acanthaceae | [20] |
| 41  | Gentipicroside | Gentianaceae | [17,24,36–38] |
| 42  | Oleuropein | Oleaceae | [35,39] |
| 43  | Qinjiaosides B | Gentianaceae | [34] |
| 44  | Qinjiaoside A | Gentianaceae | [34] |
| 45  | 6′-O-trans-cinnamoyl-secologanoside | Oleaceae | [40] |
| 46  | Sylvestroside III | Dipsacaceae | [41] |
| 47  | Sylvestroside I | Dipsacaceae | [41] |
| 48  | Sylvestroside IV | Dipsacaceae | [41] |
| 49  | Non-glycosidic iridoids | Valtrate | [44] |
| 50  | 1-β-acevaltrate | Valerianaceae | [44] |
| 51  | Acevaltrate | Valerianaceae | [44] |
| 52  | 6α-hydroxygenipi | Rubiaceae | [19] |
| 53  | 6α-methoxygenipi | Rubiaceae | [19] |
| 54  | IIHD-acevaltrate | Valerianaceae | [42] |
| 55  | garjasmine | Rubiaceae | [19] |
2.1. Iridoid Glycosides

The iridoid glycosides C-1 are polyhydroxyl linked and polyglycoside formed, and most of them are β-D-glucoside. Among the isolated iridoid glycosides, some rare new structures have been found, such as asperuloside, which has a ketone functional group at C-6. This cyclopentane ring with ketoyl function, especially at C-6, is a rare compound in the plant kingdom [45]. Besides, Iridoid glycosides with apiolofuranosyl moieties have been reported for the first time in *Sambucus williamsii* Hance. Based on the extensive spectroscopic analysis (NMR and HRESIMS) the structures were elucidated as williamsoside A and B [46].

Furthermore, 6-O-α-L-(2″-acetyl-4″-O-trans-isoferuloyl) rhamnopyranosyl catalpol is acylated and esterified at the C-2 and C-4 positions such compounds have never been separated from natural resources so far [26]. Vestena et al. isolated and purified brasoside from both *Verbena litoralis* and *Verbena montevidensis* [27]. In addition, asperuloside with a rare iridoid structure was isolated from the root and stem of *Ronabea emetica* [30]. Their structures are presented in Figure 2.

![Figure 2. Cont.](image-url)
2.2. Secoiridoids Glycosides

Secoiridoids have many structural differences compared with the iridoid glycosides [47]. Compound 42–57 are active compounds from the secoiridoid class, which are widely distributed in Gentianaceae, Nymphaeaceae, Caprifoliaceae, and Oleaceae, and other plants, and are more common in Gentianaceae and Swertia.
The C7–C8 in secoiridoids in the parent nucleus of these compounds is usually broken to form a cleavage ring. The C-7 and C-11 compounds sometimes form a 6-membered lactone structure after ring splitting. Secoiridoid rearrangements are relatively rare, and nuezhenelenoliciside is one such compound, which undergoes a break in the chemical bond between C-1 and O-2 and generates a new secoiridoid ring between C-8 and O-2. The effect of nuezhenelenoliciside on the proliferation of pre-osteoblast cells has been reported [40]. Pagide is considered the second member of the secoiridoids family of rare, naturally occurring organisms that are produced through an iridoid biosynthesis pathway based on their unique C-4 acyl substitution and C-8 glycosylation [48]. Their structures are presented in Figure 3.

In addition to the compounds, there exists a class of bis-iridoids in nature that are dimeric iridoids formed from the structures of two iridoids [9]. Cantleyoside, laciniatoside I-II, sylvestroside I, sylvestroside III-IV, sylvestrosid e III dimethyl acetal, and sylvestroside IV dimethyl acetal are mainly bis-iridoids isolated from Pterocephalus hookeri (C.B. Clarke) Höeck, which have been shown to have anti-inflammatory and analgesic activities [41]. Sclerochitonoside C has a similar structure, except that the C-7 position of the iridoid is directly connected to the C-4 position of the secoiridoid, which comprises subunits based on the 4′-hydroxyphenylethyl esters of 8-epiloganic acid and its secoiridoid analogue [43]. Furthermore, structures similar to those of laxoside have not been previously described in international catalogues. Such a structure is formed by acid hydrolysis to produce...
Their structures are presented in Figure 4. A few iridoid compounds, called non-glycosidic iridoids, are also found in nature. Mueller et al. isolated valtrate, 1-β-acevaltrate, and acevaltrate from Momordica charantia L.; these compounds did not contain glycosides, and 70 and 71 were isomers [44]. In addition, two non-glycosidic iridoids, 72 and 73, were isolated from eudodotes Gardenia jasminoides Ellis [19]. Their structures are presented in Figure 5.

2.4. Non-Glycosidic Iridoids

A few iridoid compounds, called non-glycosidic iridoids, are also found in nature. Mueller et al. isolated valtrate, 1-β-acevaltrate, and acevaltrate from Momordica charantia L.; these compounds did not contain glycosides, and 70 and 71 were isomers [44]. In addition, two non-glycosidic iridoids, 72 and 73, were isolated from eudodotes Gardenia jasminoides Ellis [19]. Their structures are presented in Figure 5.
3. Biological Activities

Now, more and more iridoids have been discovered, and their pharmacological effects are further studied, such as neuroprotective, hepatoprotective, anti-inflammatory, hypoglycemic, hypolipidemic, and antitumor activities. Their main pharmacological activities and the underlying mechanisms are shown in Figure 6.

![Figure 6. The pharmacological activity mechanism of iridoids. The blue arrow up indicates a positive or upregulated effect, while the red down arrow indicates a negative or downregulated effect. Orange circles represent some activity constituents, green ones represent the common pharmacological activities of iridoids, while represented enzymes and signaling pathways are illustrated by polygons. Abbreviations here represent the same meaning as in the body text.](image)

3.1. Neuroprotective Effects

Regeneration and repairing of the central nervous system (CNS) is a complex process with multiple links and factors [11]. Nerve growth factors (NGF) are involved in many functions of the nervous system, such as growth, survival, and regeneration, in addition to repairing the neurons from various wounds. However, they cannot penetrate the blood-brain barrier and are easily hydrolyzed by hydrolases [50,51]. Therefore, researchers are trying to find natural lipophile compounds with the properties of endogenous neurotrophic factors to induce neuronal differentiation and regeneration. To date, all the available data suggest that the iridoids are a class of natural lipophile compounds with the properties of endogenous neurotrophic factors, which could be considered as potential leads for the treatment of neurodegenerative diseases [52]. The protective effects of loganin against PD mimetic toxin 1-methyl-4-phenylpyridinium (MPP+) and the important roles of insulin-like growth factor 1 receptor (IGF-1R) and glucagon-like peptide 1 receptor (GLP-1R) in the neuroprotective mechanisms of loganin have been demonstrated. It has been shown that in primary mesencephalic neuronal cultures treated with or without MPP+, loganin protects against MPP+ -induced apoptosis by up-regulating the expression of anti-apoptotic proteins and pro-apoptotic proteins, and also enhances the expression of neurotrophic signals by up-regulating the expressions of IGF-1R, GLP-1R, p-Akt, BDNF, and...
tyrosine hydroxylase. In addition, it can reduce the production of MPP+-induced reactive oxygen species (ROS), up-regulate GAP43, and down-regulate membrane-rhoA/ROCK2/p-LIMK/p-cofilin to reduce MPP+-induced neuron damage. Furthermore, the presence of IGF-1R antagonists (AG1024) or GLP-1R antagonists (exendin 9-39) weakened the protective effect of loganin on MPP+-induced cytotoxicity and apoptosis, and decreased neuron length and ROS production. A series of experiments showed that loganin could enhance neurotrophic signals, activate IGF-1R/GLP-1R, inhibit RhoA/ROCK pathway, and alleviate MPP+-induced apoptosis and death, neuron damage, oxidative stress, and other mechanisms to achieve neuroprotective effect [53].

Studies have found that abnormal tau protein hyperphosphorylation could be one of the main causes of Alzheimer’s disease (AD). The concentration of Protein phosphatase 2A (PP2A) affects the tau protein hyperphosphorylation, which in turn is concentration-dependent. To investigate the effect of cornus iridoid glycoside (CIG) on enhancing the activity of PP2A in Cornus officinalis, Sk-N-SH cells were exposed to 20 nmol/L okadaic acid (OA, PP2A inhibitor) for 6 h to induce tau hyperphosphorylation to determine the effect of CIG on PP2A activity and on the post-translational modification of the PP2A catalytic subunit C (PP2Ac). The results showed that OA increased PP2Ac phosphorylation and tau hyperphosphorylation, while CIG preincubation significantly reduced OA-induced tau hyperphosphorylation at Ser 199/202 and Ser 396, inhibited PP2Ac phosphorylation at Tyr 307, increased Src phosphorylation, and restored PP2A activity. In conclusion, CIG can inhibit tau hyperphosphorylation by activating PP2A, reducing the p-SRC level and PP2Ac phosphorylation at Tyr307 [54]. Another compound, corn furfural B isolated for the first time from the ethanol extract of dogwood fruit, has been shown to possess neuroprotective activity by reducing the corticosterone-induced neuronal damage in PC12 cells [55]. However, the neural network is a complex system, and iridoids are a large family, with different compounds having different effects on the nervous system. Especially, the compounds with large differences in their chemical structure need to be studied in more detail. Hence, there are limitations in the study of pharmacological effects and their mechanisms.

3.2. Hepatoprotective Effects

Many studies have shown that the current effective treatments for liver disease are often associated with side effects [56]. It is highly prevalent in the current scenarios to explore the therapeutic value of natural medicinal preparations or to explore their novel effects. The hepatoprotective effects of swerodesanthin andswerodesanthin from Swertia mussotii Franch were evaluated by using the model of α-naphthol isocyanate (ANIT)-induced liver injury. After oral administration of swertiamarin (20 mg/kg) or swertianolin (20 mg/kg) for seven days, alanine transaminase, aspartate transaminase, and total direct bilirubin levels in mice were significantly reduced at α-naphthyl isothiocyanate-induced levels, while, bile flow was significantly increased (p < 0.01). The study also showed that in the cholestatic hepatitis model, the inducer ANIT could promote bile secretion; reduce AST, ALT, ALP enzyme activity; and reduce TBIL and DBIL levels which indicates the role of cycliterpene in the treatment of cholestatic hepatitis [57].

Another study tested the vegetable oil- and carbon tetrachloride-induced liver fibrosis rat models to evaluate and characterize the hepatoprotective effects of iridoid glycosides from Boschniakia rossica. The rats were continuously treated with iridoid glycosides (200 mg/kg) for 10 days and then their blood and liver tissues were harvested. When compared to the normal control group, serum ALT, AST, and TBIL levels were significantly increased in the model group (p < 0.05). HE staining and Masson staining showed that the hepatocytes in the model group exhibited degeneration, necrosis, and hepatic fibrosis. Western blot analysis showed that the expression of α-SMA was significantly increased in the liver tissue from the model control group (p < 0.05). The rats from Boschniakia rossica iridoid glucoside group showed significantly low levels of serum ALT, AST, and TBIL (p < 0.05), with markedly reduced liver fibrosis compared with that in the model control group. The expression of α-SMA in Boschniakia rossica iridoid glucoside group was significantly lower than that in the model control group (p < 0.05).
In essence, *Boschniakia rossica* iridoid glycoside could inhibit liver fibrosis by inhibiting the activation of hepatic stellate cells, which are shown to exhibit some protective effects against liver damage [58]. To determine the protective effect of CIG on hepatocyte damage induced by D-galactosamine (D-GalN) combined with TNF-α, L-02 human liver cells were cultured in vitro to establish a D-GalN/TNF-α-induced damage model in L-02 cells. The total antioxidant capacity (T-AOC) of superoxide dismutase (SOD), malondialdehyde (MDA) and intracellular calcium concentration were taken as the index, and 44 mg/L D-GalN combined with 100 µg/L TNF-α could be used as the dose in the cell damage model. The pre-protection group with high, medium, and low CIG doses (10, 20, 100 mg/L) significantly increased the activity of damaged cells and SOD activated T-AOC capacity of damaged cells, which was significantly different from that in the model group (*p* < 0.05). The activity of MDA might also have been reduced, but the decrease of MDA activity in the low concentration group was not obvious. Furthermore, western blotting showed that CIG at different concentrations significantly reduced the expression of endoplasmic reticulum stress-related protein PERK, EIF-2α, and apoptosis-associated protein caspase-3. This suggests that the mechanism may be related to the enhancement of the antioxidant capacity of cells, the reduction of damage caused by endoplasmic reticulum stress, and the reduction of the expression of apoptosis-related proteins [59]. At present, the related research on the hepatoprotective activity of iridoid compounds focuses on anti-inflammatory factors and lipid peroxide [60,61]. Some studies have shown that iridoid glycosides can also show anti-inflammatory and anti-fibrosis activity by decreasing the expression of TGF-β1 protein [62,63]. In addition, some studies have shown that promoting the opening of MPTP, resulting in the release of apoptosis factors, inhibiting the oxidation of mitochondria and respiratory chain function, making the electron transport disorder in mitochondria, interfering with ATP synthesis is also an important mechanism of liver protection [64,65]. However, the hepatoprotective activity of iridoid is less studied in the aspect of mitochondrial damage, which should be paid attention to in the future.

### 3.3. Anti-Inflammatory Activities

In the search for anti-inflammatory compounds, special interest has been directed towards iridoids [66–71]. The anti-inflammatory and analgesic activities of some diterpene components of pterygium pterygium were evaluated. The analgesic effect of *Polygonum cuspidatum* was studied by the hot plate method and acetic acid twisting method. Compared with the control group, BCPH (50, 100 mg/kg) reduced twisting times (17.25 ± 6.24 and 21.25 ± 3.65) and had a significant analgesic effect on the acetic acid-induced pain (*p* < 0.01). In the hot plate latent trial, the efficacy of a high dose of BCPH (100 mg/kg) was due to the control medicine Rotundine (20 mg/kg). The anti-inflammatory effects on carrageen-induced posterior foot swelling in rats and dimethylbenzene induced ear swelling in mice were observed. It was found that BCPH at 100 mg/kg had a significant inhibitory effect on ear edema induced by dimethylbenzene in mice. Moreover, BCPH inhibited TNF-α-induced NF-κB-dependent promoter activity in a dose-dependent manner. These results indicated that Polygonum diocyclic ether can significantly reduce the pain caused by acetic acid and reduce ear swelling in mice. At the cellular level, bis-iridoid aglycones reduced TNF-α- and LPS-induced NF-κB activation and reduced inflammatory factors (inhibiting the production of free radicals) [41].

Loganin, an iridoid glycoside present in several herbs, including *Flos lonicerae, Cornus mas* L, and *Strychnos nuxvomica*, is a valuable medication with anti-inflammatory effects [72]. To characterize the roles of loganin in osteoarthritis and its specific signaling pathway, chondrocytes were administrated with IL-1α and supplemented with or without LY294002 (a classic PI3K/Akt inhibitor). The apoptotic level, catabolic factors (MMP-3 and MMP-13 and ADAMTS-4 and ADAMTS-5), extracellular matrix (ECM) degradation, and activation of the PI3K/Akt pathway were evaluated using western blotting, PCR, and an immunofluorescent assay. The degenerative condition of the cartilage was evaluated in vivo using the Safranin O assay. The expression of cleaved-caspase-3 (C-caspase-3) was measured using immunochemistry. The results suggested that loganin suppressed the apoptosis, reduced the release of catabolic enzymes, and decreased the ECM degradation of IL-1α-induced chondrocytes.
However, suppressing PI3K/Akt signaling using LY294002, alleviated the therapeutic effects of loganin in chondrocytes. Loganin partially attenuated cartilage degradation while inhibiting the apoptotic level. This work revealed that loganin treatment attenuated IL-1ss-treated apoptosis and ECM catabolism in rat chondrocytes via regulation of the PI3K/Akt signaling, revealing that loganin is a potentially useful treatment for osteoarthritis [73]. In addition, isolated camptoside from *Camptosorus sibiricus* Rupr. (Aspleniaceae) which exhibited inhibitions of nitric oxide production in lipopolysaccharide-induced RAW 264.7 macrophages with IC50 values of 11.2 Mm [74]. Apart from the above research, the future is it necessary to inflammation related to signal transduction pathways, AA metabolic pathways of ring oxidase (COX), isomerase and its downstream of prostaglandin (PGs), synthetase system and corresponding receptors and phosphodiesterase isoenzyme more anti-inflammatory pathway and links such as anti-inflammatory effect of iridoid molecular mechanism for more in-depth research.

### 3.4. Hypoglycemic and Hypolipidemic Activities

Type 2 diabetes is a common, lifestyle-related chronic disease, and is often accompanied by various complications. The pathogenesis of type 2 diabetes is insulin resistance and dysfunction of islet β cell. Hyperinsulinemia and hyperlipidemia are important parts of insulin resistance syndrome and important risk factors of cardiovascular disease [75]. In one pharmacological investigation, it has been found that the compound of iridoids can effectively control the hyperglycemia and hyperlipidemia. The effects of CIG were studied in a mouse model of diabetes induced by a high-fat diet (HFD) and streptozotocin (STZ). The results showed that CIG (IG: 75, 150, 300 mg/kg) could significantly improve the glucose tolerance of diabetic mice, and CIG could enhance the expression of PI3K-Akt/PKB pathway-related proteins in insulin metabolism, through which the hyperglycemia and hyperlipidemia of diabetic mice induced by HFD and STZ could be improved [76].

By studying the glucose-sensing effect of Glucocorticoid (POMC) neurons genetically expressed in mutant immunoglobulin receptor 6.2 (Kir6.2) subunit (encoded by KCNJ11 gene), researchers found that this mutation can prevent ATP mediated ATP sensitive potassium pathway (KATP) closure and increase the whole-body glucose load of obese mice fed with a high-fat diet. This indicates that the loss of glucose sensing like effect of POMC neurons influences the formation of type 2 diabetes. As a membrane-permeable molecule, genipin (20 μM) can block the proton leakage mediated by uncoupling protein (UCP2), and UCP2 can negatively regulate the glucose-sensing effect of POMC neurons, resulting in the loss of glucose sensing effect. When increasing the culture of islet β cells, genipin can increase the potential of mitochondrial membrane, thus increasing the ATP level and closing the KATP pathway, stimulating glucose excitatory neurons and stimulating insulin secretion. This result showed that genipin has a potential therapeutic effect on diabetes [77].

A model of diabetes mellitus in rabbits was established by intravenous injection of alloxan at a dose of 150 mg/kg. After diabetes induction, the plasma, erythrocyte malondialdehyde (MDA) and blood glucose of all diabetic animals increased significantly. For the next 16 weeks, the treatment group took 20 mg/kg OLE orally every day. At the beginning of the treatment, compared with that in diabetic control, the blood glucose levels in rabbits increased continuously throughout the study period. The blood glucose level of the treated rabbits, however, decreased significantly in the eighth week. The results showed that the activity of superoxide dismutase (SOD), the level of MDA, and blood glucose were significantly increased, indicating that oleuropein can be used as a hypoglycemic and antioxidant agent to prevent complications and oxidative stress caused by diabetes [78]. At present, the mechanism of hypoglycemia mainly includes insulin stimulation and repair of damaged pancreas; effects on glucose metabolism; increases insulin sensitivity, improves insulin resistance, and regulates intestinal flora [79–83]. Iridoids to regulate intestinal flora’s research are also insufficiently thorough, the active ingredient from iridoid monomers adjusts the perspective of intestinal flora, by adjusting the proportion of gram-negative bacteria, adjusting the lipopolysaccharide (LPS), short chain fatty acid (SCFAs), pancreatic glucagon like peptide 1 (glp-1) and so on protein content, absorb medications
affect blood glucose metabolism, polysaccharide absorption metabolism, to iridoids for the further study of mechanism of diabetes, and pay attention to the connection between various mechanisms.

3.5. Antitumor Activities

The antitumor activities of gentiopicroside in the non-small ovarian cancer cell line (SKOV3) have been reported. The antitumor effects were investigated by exposing the SKOV3 cells to gentiopicroside (0, 7.5, 15, 30 µM) for 24 h. Thereafter, anticancer effects were determined by MTT assay, the apoptosis was investigated by DAPI and annexin V/propidium iodide (PI) double staining, mitochondrial membrane potential (MMP) determination and cell cycle analysis were carried out by flow cytometry, and protein expression was examined by western blotting. The results showed that gentiopicroside exhibited anticancer effects on SKOV3 cancer cells in a dose-dependent manner. The IC50 of gentiopicroside was found to be 20 µM against the SKOV3 cancer cells. The anticancer effects were mainly found to be a result of the loss of MMP and the induction of apoptosis. The Bax/Bcl-2 expression ratio was also altered upon gentiopicroside treatment. Furthermore, gentiopicroside could arrest the SKOV3 cells in G2/M phase of the cell cycle and prevent their migration and invasion. These results indicated that gentiopicroside could prove as a potential lead molecule in the treatment and management of ovarian cancer [84].

Valjatrate E extracted from Valeriana jatamansi Jones is a kind of iridoid with reported anti-tumor activity. The effect of HepG2 on tumor invasion, on metastasis of human hepatocellular carcinoma and its potential mechanisms have been reported. The effects of valjatrate E on the migration and invasion of HepG2 cells were determined by the wound healing experiment and the transwell room experiment, respectively. The adhesion properties of HepG2 cells were evaluated by homogeneous and heterogeneous adhesion experiments. Finally, the molecular mechanism of valjatrate E inhibiting invasion and migration of HepG2 cells was studied by gelatine enzyme spectrometry and western blot. The valjatrate E was found to exhibit antitumor properties by inhibiting metalloprotease 2 (MMP-2) and metalloprotease 9 (MMP-9) expression; by inhibiting heterogeneous adhesion; by blocking mitogen-activated protein kinase (MAPK) signal; and by inhibiting the phosphorylation of extracellular signal-regulating kinase (p-ERK). These findings provided new evidence for the important role of the MAPK/ERK signaling pathway in promoting invasion and metastasis of HepG2 cells through p-ERK. The MAPK/ERK signaling pathway may, therefore, be a therapeutic target for tumors [85].

A novel secoiridoid compound, swertiamarin B, isolated from the ethanol extract of the aerial parts of Swertia mussotii has been shown to possess antitumor activity, which has been reported against four human tumor cell lines (HCT-116, HepG2, MGC-803 and A549). The results showed that swertiamarin B had strong cytotoxic activity against MGC-803 cell line (IC50 = 3.61) and could effectively inhibit cell proliferation, suggesting that it may be a new therapeutic agent for gastric cancer [86]. The research of the anti-tumor of natural medicine has been the hotspot of scientists. Although it has been proved that iridoid compounds have antitumor activity, most of them are based on in vitro cell experiments, but few in vivo and clinical research, and the effects of the compound in vivo and in vitro may be different. It is necessary to pay attention to the combination of in vivo and in vitro experiments in the future.

3.6. Others

Apart from the actions mentioned above, iridoids also exhibit other effects, including antioxidant [44], cardio cerebrovascular activity, cholagogic effects, and α-glucosidase inhibitory activity. Table 2 summarizes the other activities of iridoids.
Table 2. Other activities of iridoids.

| Function                          | Compounds       | Dose          | Model                                                                 | Efficacy Evaluation                                                                                                                                                                                                 | Ref.          |
|----------------------------------|-----------------|---------------|----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Cardiocerebrovascular activity   | Geniposide      | 33.2 µg/mL    | Brain microvascular endothelial cell (BMEC) with oxygen-glucose deprivation (OGD) | Declining the productions of IL-8, IL-1β and monocyte chemotactic protein 1 (MCP-1)                                                                                                         | [87]          |
| Digestive activity               | Gentipicroside  | 20 mg/kg      | Male rats (Sprague Dawley; six weeks old)                             | In all experimental groups an increase of gastric juice volume, total and free HCl concentration as well as pepsin concentration was observed.                                                     | [32]          |
| Cholagogic effects               | Genipin         | 1 µmol/100 g.min | Male Sprague Dawley rats and hyperbilirubinemic rats                  | Enhanced the ability of hepatocytes to secrete independent bile salts                                                                                                                                   | [88]          |
| Antioxidant                      | Geniposide      | 12.5, 25, 50 µg/mL | Human umbilical vein endothelial cell                              | Increased the activities of SOD, GSH-Px, NOS and NO production                                                                                                                                   | [89]          |
| Antithrombotic activity          | Geniposide and genipin | 20, 40 mg/kg | Male ICR mice                                                         | Significantly prolonging the time required for thrombic occlusion                                                                                                                                    | [90]          |
| Anti-senescence                  | Catalpol        | 0.01, 0.1, 1 mg/mL | Human fibroblast Hs68 cell line irradiated by ultraviolet B (UVB) | Inhibited the formation of matrix metalloproteinase-1 (MMP-1)                                                                                                                                    | [91]          |
| Against intestinal ischemia/reperfusion (I/R) injury | Catalpol | 25, 50 mg/kg | In vivo intestinal I/R-injured rats | Significantly attenuated rat intestinal I/R injury by decreasing pro-inflammatory cytokines, reducing oxidative stress, and restoring intestinal barrier function | [92]          |
| Anti-depressive                  | Genipin         | 100 mg/kg     | CUMS rat model                                                        | Decreases in serum trimethylamine oxide (TMAO) and β-hydroxybutyrylic acid (β-HB)                                                                                                                   | [93]          |
| Wound healing properties         | Methylcatalpol  | 50 mg/kg      | Male rabbits model                                                    | Protective activity against increased skin vascular permeability                                                                                                                                | [94]          |
| Antiallergic                     | 3,4-Dihydroxy catalpol | 30 mg/kg      | Asthmatic mouse model                                                | Exhibited an antiasthmatic effect by the suppression of elevated IgE, IL-4 and IL-13 levels and eosinophilia in the plasma                                                                         | [95]          |
| Analgesic activity               | Bis-iridoid     | 50, 100 mg/kg | Male mice                                                            | Bis-iridoid inhibited TNF-α-induced NF-κB-dependent promoter activity in a dose-dependent manner, The release of several proinflammatory cytokines and mediators (including TNF-α and PGE2) contributes to nociceptor sensitization and a reduction | [7]           |
| Anti-HIV-1 activity              | 2′-O-(4-Methoxycinnamoyl) mutsaenossidic acid | 0.1 µg/mL    | Real-time polymerase chain reaction (PCR) assay and HIV-1 p24 antigen kit | The expression level of C-C chemokine receptor type 5 (CCR5) and chemokine receptor type 4 (CXCR4) on CD4+ T cells were decreased in cells treated with this iridoid glycoside, demonstrated that this iridoid glycoside restricts HIV-1 replication on the early stage of HIV infection | [35]          |
| Antiproliferative activities     | Deacetyl asperuloside | 806.4 µg/mL | K562 chronic myelogenous leukemia cells                             | Significantly increased caspase 3 activity (p < 0.05)                                                                                                                                                  | [16]          |
| AChE inhibitory                  | Lupulinoside    | 134.0 µM      | GST, AChE                                                             | Lupulinoside exhibited different levels of GST, AChE inhibitory                                                                                                                                | [41]          |
| Anti-obesity                     | Genipin         | 20 mg/kg      | High-fat diet-fed obese mice                                         | Regulating miR-142a-5p/SREBP-1c axis, led to the inhibition of lipogenesis                                                                                                                           | [96]          |
| Anti-osteoporosis activity       | Aucubin         | 1, 2.5, 5 µM  | MG63 cells                                                            | Improved osteoblast differentiation and enhanced the levels of BMP2 (bone morphogenic proteins-2) in MG63 cells                                                                                   | [97]          |
|                                 | Nuezhenelenoliciside | -            | MC3T3-E1 cells                                                       | Increased the proliferation of pre-osteoblast MC3T3-E1 cells, possessed anti-osteoporosis activity                                                                                               | [11]          |
| Function                          | Compounds                  | Dose               | Model                                      | Efficacy Evaluation                                                                                                                          | Ref. |
|----------------------------------|---------------------------|--------------------|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|------|
| Inhibition of gastric lesions    | Genipin                   | 50, 100 mg/kg (p.o.) | HCl/ethanol-induced gastric lesions rat    | Increasing ROS and ROS-induced NAPDH-oxidase (NOX) production and enabling gastric cancer cells to start the tumor cell apoptosis process via Egr1/p21 signaling pathway | [98] |
| Anti-Alzheimer’s disease         | Gardenoside               | -                  | Fruit-fly Alzheimer’s disease model induced by human Abeta protein over-expression | Suppressed the expression of immune-related genes in the brain                                                                             | [99] |
| Anti-angiogenic                  | Geniposide                | 25–100 µM          | NIH3T3 cell line                          | Dose-dependently inhibiting the growth of the transformed NIH3T3 cell line                                                                    | [100]|
| Inhibition of rheumatoid arthritis | Geniposide               | 50 µM              | MHTA fibroblast-like synoviocytes in patients with rheumatoid arthritis | Inhibition of TNF-α-stimulated cell proliferation and activation of the Ras-Erk1/2 pathway via upregulating miRNA-124a expression          | [101]|
| α-Glucosidase inhibitory activities | Aldosecolloganin          | 0.5 mM             | Lipopolysaccharide (LPS)-induced nitric oxide (NO) production and α-glucosidase reagent   | Inhibiting α-glucosidase with IC50 values of 1.08 ± 0.70 and 0.62 ± 0.14 mM                                                                | [102]|
| Anti-anxiety properties          | Geniposide                | 20, 40 mg/kg       | Male ddY mice 4 weeks of age               | Increased the social interaction time and demonstrated to exert an anxiolytic effect in a dose-dependent manner                             | [103]|
| Antiviral                        | 6-O-trans-p-coumaroyl-8-O-acetylshanzhiside methyl ester | 42.2 µg/mL         | The viral CPE assay                       | Have potent in vitro activity against respiratory syncytial virus (EC50 2.46 µg/mL, IC50 42.2 µg/mL)                                       | [104]|
| Angiogenic properties            | Aucubin                   | 10 mg/kg           | Female C57BL/6 mice                       | Induced angiogenesis via vascular endothelial cell growth factor (VEGF)/Akt/endothelial nitric oxide synthase (eNOS) signaling pathway | [105]|
| Sedative effect                  | Total iridoids            | 0.3, 0.6, 0.9 g/kg | Male mice                                 | Reduce the number of autonomous activities, prolong the sleep time of mice, and strengthen the hypnotic effect of pentobarbital sodium | [106]|
| Anticonvulsant                   | Total iridoids            | 1.0, 1.5, 2.0 g/kg | Pentetrazol-induced mice epilepsy model   | Reduce the mortality of mice and prolong the latent period of convulsion                                                                 | [106]|
| Improving irritable bowel syndrome | Total iridoids           | 0.3 mg/kg          | Irritable bowel syndrome model rats       | Regulating TPH1 and MAO-A factor, reducing 5-HT expression in serum and visceral sensitivity in rats with irritable bowel syndrome       | [107]|
| Antibacterial activity           | Philosyoside I, Philomiel, Pulchelloside I | -                 | 12 different strains                      | Exhibited from low to moderate levels (MIC = 0.05–0.50 µg/mL) of antibacterial activity                                                   | [108]|
| Antimalarial activity            | Epoxygaertneroside, Methoxygaertneroside, Gaertneroside, Acetylgamertneroside, Gaertneric acid | 1.3, 2.3, 4.3, 5.4, and 7.1 mg/mL | MT-4 cells                               | Displayed antiamoebic activity with ICS0 values of 1.3, 2.3, 4.3, 5.4, and 7.1 mg/mL                                                  | [109]|
| DNA polymerase inhibitory        | Catalpol, 8-O-acetylharpagide, Harpagide | 47.8 mM            | Adequate primer/template DNA and nucleotide analogues | Inhibition of tag DNA polymerase activity with an IC50 value of 47.8 mM                                                                         | [110]|
| Anti-melanogenesis activity      | 9-epi-6α-methoxy geniposidic acid, Asperulosidic acid, Deacetyl asperulosidic acid, Scandoside methyl ester | 100 mM         | B16 melanoma cells induced by α-melanocyte-stimulating hormone (α-MSH) | Exhibited anti-melanogenesis activity with 40–50% reduction of melanin content at 100 mM                                                      | [111]|
4. Pharmacokinetic of Iridoids

In recent years, iridoids have been proven to have a wide range of biological activities, and their pharmacokinetic characteristics have also been widely studied [112]. The different structures of parent nuclei of iridoids result in different metabolic pathways, mainly through the hydrolysis of β-glucosidase, glucose-aldehydeification, isomerization, and other metabolic processes throughout the body [8]. The pharmacokinetics have been defined based on the different structures of the parent nucleus.

4.1. Iridoid Glycosides

The pharmacokinetics of iridoid glycosides are summarized based on several active compounds as examples, including geniposide and agnuside.

In general, glycosides do not work directly in the blood, but in the digestive system enzymes, stomach acid, intestinal bacteria, intestinal membrane enzymes, and other changes into another structure, and then plays a role. The in vivo and in vitro studies using the intestinal perfusion and Caco-2 model demonstrated that geniposide absorbed by passive diffusion had better absorption in the duodenum and jejunum from the intestinal perfusion model, suggests that the correlation between the pattern of use and bioavailability. On the other hand, verapamil influenced the transportation of geniposide, while EDTA did not which indicated that the absorption of geniposide in vivo may involve the active efflux mechanism mediated by P-glycoprotein [113]. The discovery of gardenoside in the brain suggests that it can pass through the blood-brain barrier for therapeutic purposes [114]. The pharmacokinetics of geniposide in rats with type 2 diabetic rats had higher C_{max}, larger area under curve (AUC), longer T_{max}, lower clearance rate (CL), and shorter mean residence time (MRT) (p < 0.05), compared to the healthy rats. The variable results that are attributed to geniposide can be hydrolyzed to aglycone by β-glucosidase produced by intestinal epithelia cells and absorbed into the blood circulation in the type 2 diabetic rats [115]. Yang et al. studied the effects of G. jasminoides extract on rat liver, and the oral results showed that the extract was significantly better than genipin, possibly because the main component of the water extract, gardenia glycoside, was better dispersed in the gastrointestinal tract and was easier to be absorbed through intestinal epithelial cells after being decomposed into ginipin by intestinal microorganisms [116]. The metabolic processes of genistein are shown in Figure 5. After intravenous administration of naosuning injection mainly containing geniposide, 70 percent of the urine was excreted within 10 h, suggesting that excretion through the kidney was the main excretion mode of the geniposide [117]. The metabolic process of geniposide is shown in Figure 7.

Similarly, one study determined the content of agnuside in mouse plasma and various tissues such as liver, spleen, kidney, lung, and brain. The total agnuside exposure (AUC_{0→∞}) was highest in the small intestine, followed by kidney and liver, while the heart had the lowest of it. AGN is detected in the brain within 24 h, indicating it could effectively cross the blood-brain barrier and the selective retention in the brain. When taken orally for 0.5 h (T_{max}), the serum concentration of agnuside increased rapidly (C_{max} = 422.33 ± 10.73 ng/mL, half-life (T_{1/2}) = 0.90 ± 0.16 h), indicating that agnuside could be rapidly absorbed and distributed in tissues. At the same time, the apparent distribution volume (Vd) of agnuside was 143.02 ± 79.02 L/kg, indicating that agnuside is more widely distributed in tissues than in plasma. On the other hand, the C_{max} value of agnuside when injected intravenously (62,852.32 ± 13,013.94 ng/mL) was significantly higher than that of the oral administration. It is the highest in the intestine, which may be the reason for its low oral bioavailability, and it could be cleared out of all tissues within 8 h. Agnuside had the highest content in the intestine, followed by the kidney, indicated that it plays an important role in the extrahepatic clearance as the main excretory organ [118]. At present, there have been some studies on the pharmacokinetics of iridoids, but only limited to a few compounds, the pharmacokinetics of this class of compounds should be fully explored, and their metabolites and mechanisms should be comprehensively and systematically studied.
which can contribute to the gentiopicroside metabolism [123–125]. In feces samples, it is speculated that GPS reportedly transforms into five active constituents, SWS is metabolized by intestinal bacteria by the first-pass effect. Gentiopicroside, swertiamarin, and sweroside are mainly excreted by the kidneys and in lower amounts in the bile and feces [126]. The metabolic processes of gentiopicrosin are shown in Figure 8.

High-performance liquid chromatography-electrospray tandem mass spectrometry (LC-ESI-MS/MS) was used to determine the picroside I-III levels in rat plasma and tissue homogenates. Three compounds were found to be widely distributed and quickly eliminated. In addition, picroside I-II were also found to be able to rapidly pass the blood-testicular barrier, but not the blood-brain barrier [127]. In addition, the highest concentrations of picroside I and III were found in kidneys, while picroside II was found in the liver. Moreover, it was found that picroside II exhibits the slowest metabolism with the terminal elimination half-lives (T1/2) were reported to be 0.941 ± 0.235 h [96]. Another study showed that because picroside I, II has a lipophilic and ionizable state, it can be completely metabolized [128].

Figure 7. The metabolic processes of geniposide.

4.2. Secoiridoids

The metabolism of the secoiridoids such as gentiopicroside, swertiamarin, sweroside, and picroside-I, II, and III has been reviewed in the following section.

The structure of both gentiopicrin and sweroside are similar to swertiamarin, but for swertiamarin, it is hard to penetrate the blood-brain barrier [119]. In the model of rats, gentiopicrocin and swertiamarin are found to be hydrolyzed by bacterial beta-glucosidase to form aglycones, which is then transformed into iso-coumarin derivative erythrin lactone. Under the action of the liver and intestinal bacteria, gentiopicrocin undergoes reactions such as isomerization and lysis to form the final metabolite to be expelled from the body, where swertiopicrin is converted into isocoumarin and nitrogen-containing metabolite [120]. The isocoumarins and alkaloids produced during metabolism are the pharmacodynamic components of gentiopicrocin and Swertia picroside in rats [121,122]. Another study showed that gentiopicrosin might be inhibited or induced by cytochrome P450 enzymes, which, which can contribute to the gentiopicrosin metabolism [123–125]. In feces samples, it is speculated that GPS reportedly transforms into five active constituents, SWS is metabolized by intestinal bacteria by the first-pass effect. Gentiopicrosin, swertiamarin, and sweroside are mainly excreted by the kidneys and in lower amounts in the bile and feces [126]. The metabolic processes of gentiopicrosin are shown in Figure 8.
Another study showed that because picroside I, II has a lipophilic and ionizable state, it can be completely metabolized [128].

Figure 8. The metabolic processes of gentiopicrin.

4.3. Others

In addition to the aforementioned compounds, bis-iridoids and non-glycosidic iridoids have a wide range of pharmacological effects, and their in vivo metabolism has also been studied.

Studies have found that intestinal bacteria can convert geniposide to genipin. After sulfatase (type H-1) hydrolysis of plasma samples, many genipins appeared, indicating that genipin sulfate is the main metabolite of genipin. Furthermore, both oral administration and injection of genipin could quickly detect the presence of genipin sulfate, indicating that genipin sulfate is produced when passing through the intestines and liver. When administered to rats at doses of 200 mg/kg, genipin was found to be highly toxic. Therefore, the dose of genipin should be properly formulated to ensure safety [129]. Another study found that the plasma concentration of apocynin can reach $C_{\text{max}}$ at 504.42 ± 1.14 ng/mL within 6 h, and it has the largest $\text{AUC}_{0-t}$ value compared with picroside I and II. Apocynin can be quickly absorbed but is eliminated slowly. Meanwhile, HPLC analysis of urine from the rat showed no detection of apocynin, indicating that apocynin can be completely metabolized in vivo, which could be because of its high lipophilicity and ionizability [128].

Iridoids mostly exist in the form of glycosides, and its metabolic process has undergone $\beta$-glycosidase enzymes hydrolysis, glucose metabolism aldehyde acidification, and isomerization. However, in vivo, metabolism is a complex process, the metabolism of each compound has its own characteristics, the metabolic mechanism of the compound is not limited to a certain way. At present, the research on the pharmacokinetics of iridoids mainly focuses on the pharmacokinetics of medicine absorption, distribution, metabolism, and excretion, with less research on the mechanism and more focused on intestinal metabolism, but less on the mechanism of other metabolic sites in vivo. Therefore, we should systematically study the metabolic mechanism of iridoid and consider the interaction between the mechanisms.
5. Conclusions

Iridoids are a type of natural products widely distributed in the plant kingdom, which have a variety of biological activities and prodrug characteristics, with high medicinal value. Modern pharmacological studies have found that these compounds have anti-tumor, anti-depression, liver-protecting, neuroprotective, and other biological effects. The anti-tumor activity and therapeutic effects of iridoid on diabetes have been widely studied; it was found that ether terpenes can also inhibit DNA polymerase activity, suggesting that new anti-tumor medicine can be developed to inhibit DNA synthesis.

In recent years, with the continuous improvement in extraction methods and storage conditions, increasing numbers of iridoids have been identified. However, they are prone to degradation under both physical and chemical stress conditions and have poor chemical stability, which produces limitations in the study of their monomers, and hinders the study of their activities and functions. Moreover, most of the studies on iridoids are still focused on the determination of their structures and analysis of their activities. There is a lack of systematic research on their structure types and structure-activity relationship. Therefore, the analysis of and comparative studies on the structure and function of iridoids should be further intensified, to better confirm the main active functional groups and effects of iridoids, and provide effective data support for chemical modification and new medicine development, which will be a new hotspot of studies on natural products.

Several recent studies have shown that a variety of iridoids can be used as a therapeutic medicine for intracerebral targeting because they can pass the blood-brain barrier. However, the content distribution in the brain is low, and the compounds undergo rapid absorption and elimination in vivo and wide distribution to tissues and organs and have low biological benefits when administered by the oral route. The metabolic process for iridoids in vivo was mainly studied in animal models such as rats and mice; however, the metabolic process and pharmacokinetic parameters in the human body have been rarely studied. There are a few toxic and side effects reported—however, there is a lack of research on the preparation of iridoid monomers for use in clinical treatment. Therefore, in-depth studies on iridoids are necessary to improve their bioavailability and to develop new dosage forms after a detailed study on their toxicity.

In summary, recently, new structures and effects of iridoids have been elucidated at a rapid rate. In vivo characterization of iridoids will help determine the pharmacodynamic properties and explore the therapeutic potential of compounds used in medicine. The types, constituents, pharmacological activities, and metabolism of iridoids have been systematically summarized in this review to lay a foundation for further studies on iridoid glycosides.

Author Contributions: Conceptualization, M.L.; Methodology, C.W. and M.L.; Original draft preparation, C.W., X.G., M.Z., E.Z.; Software, L.Z.; Supervised, A.B. and M.L.; Review and editing, C.Z. and M.L. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by National Natural Science Foundation of China (grant no. 81760776), National Natural Science Foundation of China (grant no. 81874336), Natural Science Foundation of Inner Mongolia Autonomous Region (grant no. 2018ZD13), 2018 Chinese medicine public health service subsidy special “the fourth survey on Chinese materia medica resource” (grant no. Finance Society [2018] 43), China Agriculture Research System (grant no. CARS-21).

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Li, C.M.; Luo, Y.W.; Tian, B.Y. Research Progress on Mass Spectral Fragmentation of Iridoids. *J. Hebei Norm. Univ. (Nat Sci. Edit).* 2015, 39, 522–526.
2. Pei, Y.H.; Lou, H.X. Natural Medicinal Chemistry; People’s Health Publishing House: Beijing, China, 2016; pp. 192–195.
3. Bianco, A. Recent developments in iridoids chemistry. *Pure Appl. Chem.* 1994, 66, 2335–2338. [CrossRef]
4. Zheng, L.S.; Liu, X.Q. Research progress of iridoids. *Res. Dev. Nat. Prod.* 2009, 21, 702–711.
5. Ren, Z.J.; Zhang, L.M.; He, K.Z. Extraction Technology and Pharmacological Research Progress of Main Components of Gardenia jasminoides Ellis. Res. Dev. Nat. Prod. 2005, 17, 831–836.

6. Picerno, P.; Autore, G.; Marzoccio, S.; Meloni, M.; Sanogo, R.; Aquino, R.P. Anti-inflammatory activity of verminoside from kigelia a fricana and evaluation of cutaneous irritation in cell cultures and reconstituted human epidermis. J. Nat. Prod. 2005, 68, 1610–1614. [CrossRef] [PubMed]

7. Akihisa, T.; Matsumoto, K.; Tokuda, H.; Yasukawa, K.; Seino, K.I.; Nakamoto, K.; Kimura, Y. Anti-inflammatory and potential cancer chemopreventive constituents of the fruits of Morinda citrifolia (Noni). J. Nat. Prod. 2007, 70, 754–757. [CrossRef]

8. Dong, J.E.; Zhang, J. Advances in the Research of Iridoids Occurring in Plants. J. Northwest For. Univ. 2004, 19, 131–135.

9. El-Naggar, L.J.; Beal, J.L. Iridoids. A review. J. Nat. Prod. 1980, 43, 649–707. [CrossRef]

10. Zheng, H.R.; Zhu, Y.; Li, W.; Ding, L. Research progress on pharmacokinetics of natural iridoids. Drug Eval. Res. 2018, 41, 217–223.

11. Wang, F.F.; Zhang, Y.M.; Zheng, X.W.; Dai, Z.; Liu, B.; Ma, S.C. Research Progress of the Structure and Biological Activities of Iridoids Compounds. China Acad. J. Electron. Publ. House 2019, 33, 91–98.

12. Tundis, R.; Loizzo, M.; Menichini, F.; Statti, G.A.; Menichini, F. Biological and Pharmacological Activities of Iridoids: Recent Developments. Mini Rev. Med. Chem. 2008, 8, 399–420. [CrossRef] [PubMed]

13. Li, M.; He, X.; Tao, R.; Cao, X.Y. Phytochemistry and Pharmacology of the Genus Pedicularis Used in Traditional Chinese Medicine. Am. J. Chin. Med. 2014, 42, 1071–1098. [CrossRef] [PubMed]

14. Fu, J.J.; Jin, H.Z.; Shen, Y.H.; Qin, J.J.; Wang, Y.; Huang, Y.; Zeng, Q.; Zhang, W.D. Chemical constituents of Verbena litoralis and their main iridoid, brasoside. J. Ethnopharmacol. 2019, 239, 111906. [CrossRef]

15. Behbahani, M. Evaluation of anti-HIV-1 activity of a new iridoid glycoside isolated from Verbena montevidensis and their antiproliferative activities. J. Ethnopharmacol. 2018, 201, 1459–1464. [CrossRef] [PubMed]
29. Adom, M.B.; Taher, M.; Mutalabisin, M.F.; Amri, M.S.; Kudos, M.B.A.; Sulaiman, M.W.A.W.; Sengupta, P.; Susanti, D. Chemical constituents and medical benefits of Plantago major. *Biomed. Pharmacother.* **2017**, *96*, 348–360. [CrossRef]

30. Berger, A.; Fasshuber, H.; Schinnerl, J.; Robien, W.; Brecker, L.; Valant-Vetschera, K. Iridoids as chemical markers of false ipecac (*Ronbea emetica*), a previously confused medicinal plant. *J. Ethnopharmacol.* **2011**, *138*, 756–761. [CrossRef]

31. Saracoglu, I.; Harput, U.S. In Vitro Cytotoxic Activity and Structure Activity Relationships of Iridoid Glucosides Derived from Veronica species. *Phytother. Res.* **2012**, *26*, 148–152. [CrossRef]

32. Shancai, T.; Qiuxia, L.; Yueyue, S.; Yiran, S.; Fang, C.; Lin, T. Iridoid Glycosides Fraction Isolated from *Veronica ciliata* Fisch. Protects against Acetaminophen-Induced Liver Injury in Mice. *Evid.-Based Complement. Altern. Med.* **2017**, *2017*, 6106572.

33. Khan, M.F.; Dixit, P.; Jaiswal, N.; Tamrakar, A.K.; Srivastava, A.K.; Maurya, R. Chemical constituents of *Kigelia pinnata* twigs and their GLUT4 translocation modulatory effect in skeletal muscle cells. *Fitoterapia* **2012**, *83*, 125–129. [CrossRef] [PubMed]

34. Lv, T.; Xu, M.; Wang, D.; Zhu, H.T.; Yang, C.R.; Zhang, T.T.; Zhang, Y.J. The chemical constituents from the roots of *Gentiana crassicaulis* and their inhibitory effects on inflammatory mediators NO and TNF-α. *Nat. Prod. Bioprospect*. **2012**, *2*, 217–221. [CrossRef]

35. Gao, B.B.; She, G.M.; She, D.M. Chemical Constituents and Biological Activities of Plants from the Genus Ligustrum. *Chem. Biodivers.* **2013**, *10*, 96–128. [CrossRef] [PubMed]

36. Li, J.; Zhang, J.; Zhao, Y.L.; Huang, H.Y.; Wang, Y.Z. Comprehensive Quality Assessment Based Specific Chemical Profiles for Geographic and Tissue Variation in *Gentiana rigescens* Using HPLC and FTIR Method Combined with Principal Component Analysis. *Front. Chem.* **2017**, *5*, 125. [CrossRef] [PubMed]

37. Khobrakova, V.B.; Budaeva, E.R.; Olennikov, D.N.; Zilfikarov, I.N. Immunomodulating Activity of Extract of *Gentiana alida* Pall. *Pharm. Chem. J.* **2017**, *51*, 384–387. [CrossRef]

38. Zhang, L.; Zou, D.Z.; Bai, S.; Li, Z.H.; Zhang, C.H. Chemical constituents from *Gentianella turkestana* (Gentianaceae). *Biochem. Syst. Ecol.* **2016**, *65*, 89–92. [CrossRef]

39. Gao, L.; Li, C.; Wang, Z.; Liu, X.Q.; You, Y.; Wei, H.; Guo, T. Ligustri Lucidi Fructus as a traditional Chinese medicine: A review of its phytochemistry and pharmacology. *Nat. Prod. Res.* **2015**, *29*, 493–510. [CrossRef]

40. Qiu, Z.C.; Zhao, X.X.; Wu, Q.C.; Fu, J.R.; Dai, Y.; Wong, Z.S.; Yao, X.S. New secoiridoids from the fruits of *Ligustrum lucidum*. *Chem. Nat. Compd.* **2013**, *50*, 287–290. [CrossRef] [PubMed]

41. Chen, Y.; Yu, H.; Guo, F.; Wu, Y.C.; Li, Y.M. Antinociceptive and anti-inflammatory activities of a standardized extract of bis-iridoids from *Pterocephalus hookeri* from *Ronbea emetica*. *Evid.-Based Complement. Altern. Med.* **2017**, *2017*, 960514. [CrossRef] [PubMed]

42. de Ávila, J.M.; Pereira, A.O.; Zachow, L.L.; Gehm, A.Z.; Santos, M.Z.; Mostardeiro, M.A.; Back, D.; Morel, A.F.; Dalcol, I.I. Chemical constituents from *Valeriana polystachya* Smith and evaluation of their effects on the acetylcholinesterase and prolyl oligopeptidase activities. *Fitoterapia* **2018**, *131*, 80–85. [CrossRef] [PubMed]

43. Brown, A.S.S.; Veitch, N.C.; Simmonds, M.S.J. Leaf Chemistry and Foliage Avoidance by the Thrips *Frankliniella occidentalis* and *Heliothrips haemorrhoidalis* in Glasshouse Collections. *J. Chem. Ecol.* **2011**, *37*, 301–310. [CrossRef] [PubMed]

44. Mueller, L.G.; de Andrade Salles, L.; Sakamoto, S. Effect of Storage Time and Conditions on the Diene Valepotriates Content of the Extract of *Valeriana glechomifolia* Obtained by Supercritical Carbon Dioxide. *Phytochem. Anal.* **2012**, *23*, 222–227. [CrossRef] [PubMed]

45. Ralambonirina Rasoarivelo, T.S.; Grougnet, R.; Michel, S.; Guillou, C.R.; Deguin, B. Chemical study of *Anthospermum eminere* (Rubiaciae). *Biochem. Syst. Ecol.* **2017**, *70*, 186–191. [CrossRef]

46. Wang, Z.Y.; Han, H.; Yang, B.Y.; Xia, Y.K.; Kuang, H.X. Two New Iridoid Glycosides from the Root Barks of *Sambucus williamsii* Hance. *Molecules* **2011**, *16*, 3869–3874. [CrossRef] [PubMed]

47. Dinda, B. *Pharmacology of Iridoids; Pharmacology and Applications of Naturally Occurring Iridoids*; Springer: Cham, Switzerland, 2019; pp. 1–15. [CrossRef]

48. Qi, J.; Li, N.; Zhou, J.; Yu, B.Y.; Qiu, S.X. Isolation and Anti-Inflammatory Activity Evaluation of Triterpenoids and a Monoterpene Glycoside from *Harpagophyton procumbens*. *Planta Med.* **2010**, *76*, 1892–1896. [CrossRef]

49. Alaniya, M.D.; Sutiashevili, M.G.; Shalashvili, K.G.; Skhirtladze, A.V.; Mshvidladze, V.D.; Pichette, A. Iridoid Glycosides from Roots of *Verbascum laxum*. *Chem. Nat. Compd.* **2014**, *50*, 842–845. [CrossRef]

50. Xu, R.X. The mechanism and effect of nerve growth factor in nerve injury repair. *Chin. J. Neurotrauma Surg. (Electron. Ed.)* **2016**, *2*, 1–4.
51. Dong, T.J.; Cui, Y.L.; Tian, J.S.; Yao, K.D. Advances in studies on natural iridoids. *Chin. Tradit. Herb. Drugs.* 2011, 42, 185–194.

52. Habtemariam, S. Iridoids and Other Monoterpenes in the Alzheimer’s Brain: Recent Development and Future Prospects. *Molecules.* 2018, 23, 117. [CrossRef]

53. Tseng, Y.T.; Lin, W.J.; Chang, W.H.; Lo, Y.C. The novel protective effects of loganin against 1-methyl-4-phenylpyridinium-induced neurotoxicity: Enhancement of neurotrophic signaling, activation of IGF-1R/GLP-1R, and inhibition of RhoA/ROCK pathway. *Phytother. Res.* 2019, 33, 690–701. [CrossRef] [PubMed]

54. Yang, C.C.; Kuai, X.X.; Zhang, L.; Li, Y.L.; Li, L.; Zhang, L. Effect of corneil iridoid glycoside on PP2Ac phosphorylation in okadaic acid-induced neurotoxicity cells. *Acta Pharm. Sin.* 2018, 53, 1036–1041.

55. Ji, L.; Wang, X.; Li, J.; Zhong, X.; Zhang, B.; Juan, J.; Zhang, X. New Iridoid Derivatives from the Fruits of *Cornus officinalis* and Their Neuroprotective Activities. *Molecules* 2019, 24, 625. [CrossRef] [PubMed]

56. Chester, K.; Paliwal, S.; Khan, W.; Ahmad, S. UPLC-ESI-MS and HPTLC Method for Quantitative Estimation of Cytotoxic Glycosides and Aglycone in Bioactivity Guided Fractions of *Solanum nigrum* L. *Front. Pharm.* 2017, 8, 434. [CrossRef]

57. Tian, C.; Zhang, T.; Wang, L.; Shan, Q.; Jiang, L. The hepatoprotective effect and chemical constituents of total iridoids and xanthones extracted from *Saweria mussotii* Franch. *J. Ethnopharmacol.* 2014, 154, 259–266. [CrossRef]

58. Li, D.X.; Jin, Y.R.; Jin, H.Y.; Li, C.H. Protective effects and the mechanisms of *Boschniakia rossica* iridoid glycoside on liver fibrosis in rats. *J. Med. Sci. Yantian Univ.* 2016, 39, 175–178.

59. Ma, Y.X.; Wu, M.H.; Jiang, Z.Q.; Zhao, F.M.; Li, L.; Li, M.H.; Lu, T.L.; Hang, A.W. Protective effect of corneil iridoid glycoside on hepatocytes injured by D-galactosamine/tumor necrosis factor-α. *Chin. Pharmacol. Bull.* 2018, 34, 118–122.

60. Wang, L.H.; Ji, H.; Zhang, B.T.; Xiao, P.Z.; Zhang, B. Research Progress on Hepatoprotective Effect of Chinese Herbal Medicine. *Addit. World.* 2012, 11, 41–45.

61. Liu, Y.; Yao, H.; Huang, H. Research progress on hepatoprotective effect of Uygur medicines. *Northwest Pharm.* J. 2018, 33, 279–284.

62. Zhu, W.J. Preventive and Therapeutic Effects of Iridoid Glycosides from *Paederia Scandens* on Uric Acid Nephropathy in Rats and Its Mechanisms. Master’s Thesis, Anhui Medical University, Hefei, China, May 2013.

63. Guo, J.; Zhang, X.S.; Liu, J.P. Regulation of iridoid glucosides from *Corni officinalis* Fructus on AGEs-induced inflammatory response in renal mesangial cells. *Chin. Tradit. Pat. Med.* 2013, 35, 2067–2072.

64. Liang, l.; Bi, Q.; Dong, J.C.; Yang, X.X.; Yu, J. Progress on the development of natural medicine with hepatoprotective effects. *Biot. Resour.* 2018, 40, 148–158.

65. Zhao, D.D.; Li, X.K.; Yu, N.; Mu, Q.Q.; Zhang, Y.; Fang, X.; Mo, F.F.; Gao, S.H. Effects of Iridoid Glycoside Extract from *Corni Fructus* Extract on Mitochondrial Oxygen Consumption and related Genes Expression in 3T3-L1 Mature Adipocytes. *Chin. J. Exp. Tradit. Med. Formulae* 2016, 22, 122–126.

66. Ma, G.H.; Zhang, L.Q.; Qian, F.; Chen, K.X.; Xu, J.W.; Li, Y.M. Research progress on anti-inflammatory activity of three kinds of iridoid glycosides in Chinese materia medica. *Chin. Tradit. Herb. Drugs.* 2019, 50, 225–233.

67. Luo, S.H.; Fu, S.C. The progress of study on anti-inflammatory mechanism of Chinese medicine. *Pharm. Care Res.* 2003, 3, 47–49.

68. Huan, B.; Lei, X.Y. Progress in the research on the anti-inflammatory effect of traditional Chinese medicine and its mechanism. *Chin. J. Clin. Ration. Med. Use* 2015, 8, 177–179.

69. Miao, Y.L.; Zhang, W.X.; Wang, Y.E.; Li, Y.; Yue, Y.H.; Ni, Y. Anti-inflammatory Mechanism of Antipyretic and Detoxicifying Traditional Chinese Medicine. *Chin. J. Exp. Tradit. Med. Formulae* 2018, 24, 228–235.

70. Li, J.; Yu, X.; Ma, Y.X.; Li, X.R. Advances in the research on anti-inflammatory mechanism of traditional Chinese medicine and its active components. *Acta Chin. Med. Pharmacol.* 2010, 38, 134–137.

71. Suh, W.S.; Kwon, O.K.; Lee, T.H.; Subedi, L.; Kim, S.Y.; Lee, K.R. Secoiridoid Glycosides from the Twigs of *Ligustrum obtusifolium* Possess Anti-inflammatory and Neuroprotective Effects. *Chem. Pharm. Bull.* 2018, 66, 78–83. [CrossRef]

72. Lei, X.X.; Su, Y.Y.; Li, M.Y.; Gui, H. Research progress of loganin and morroniside from cornel iridoid glycosides. *Shanghai J. Tradit. Chin. Med.* 2018, 52, 104–108.
73. Yang, Y.; Gu, Y.T.; Zhao, H.; Zhang, S.L. Loganin Attenuates Osteoarthritis in Rats by Inhibiting IL-1β-Induced Catabolism and Apoptosis in Chondrocytes Via Regulation of Phosphatidylinositol 3-Kinases (PI3K)/Akt. *Med. Sci. Monit.* 2019, 25, 4159–4168. [CrossRef]

74. Wang, F.; Jia, Q.W.; Yuan, Z.H.; Lv, L.Y.; Li, M.; Jiang, Z.B.; Liang, D.L.; Zhang, D.Z. An anti-inflammatory C-steryl iridoid from *Camptosorus sibiricus* Rupr. *Fitoterapia* 2019, 134, 378–381. [CrossRef] [PubMed]

75. Zhang, L.; Weimin, L.I. Retrospective Study of the Efficacy of Acarbose Combined with Metformin in the Treatment of Type 2 Diabetes Complicated with Hyperlipidemia. *China Pharm.* 2017, 20, 284–286.

76. Jiefang, K.; Chen, G.; Rodolfo, T. Hypoglycemic and hypolipidemic effects of iridoid glycosides extracted from Corni fructus: Possible involvement of the PI3K–Akt/PKB signaling pathway. *RSC Adv.* 2018, 8, 30539–30549.

77. Parton, L.E.; Ye, C.P.; Coppari, R. Glucose sensing by POMC neurons regulates glucose homeostasis and is impaired in obesity. *Nature* 2007, 449, 228–232. [CrossRef]

78. Al-Azzawie, H.F.; Alhamdani, M.S.S. Hypoglycemic and antioxidant effects of oleuropein in alloxan-diabetic rabbits. *Life Sci.* 2006, 78, 1371–1377. [CrossRef]

79. Chen, Y.; Liu, D.C. Research progress on mechanism of hypoglycemic Chinese medicine. *Chin. J. Clin. Ration. Drug Use* 2017, 10, 159–161.

80. Zhang, M.; Wang, H.H.; Zang, L.Q. Research progress on ingredients and medmechanisms of hypoglycemic traditional Chinese medicines. *J. Guangdong Pharm. Univ.* 2011, 3, 320–323.

81. Chen, M.L.; Hou, X.T.; Hao, E.W.; Du, Z.C.; Xie, J.L.; Qin, J.F.; Deng, J.G. Research progress on the pharmacological action and mechanism of hypoglycemic action of traditional Chinese medicine. *J. Chin. Med. Mater.* 2018, 41, 2016–2020.

82. Sun, Y.; Lan, M.; Chen, X.; Dai, Y.; Zhao, X.; Wang, L.; Zhang, T.T.; Li, Y.B.; Zhu, J.L.; Zhang, X.M.; et al. Anti-invasion and anti-metastasis effects of geniposide on human umbilical vein endothelial cell injury and suppression of MAPK/ERK signaling pathway. *Biomed. Pharmacother.* 2018, 104, 817–824. [CrossRef] [PubMed]

83. Yao, D.D.; Shu, L.; Yang, L.; Jia, X.B. Advance in studies on anti-diabetic mechanism of Gardeniae Fructus and its active ingredient geniposide. *China J. Chin. Mater. Med.* 2014, 8, 1368–1373.

84. Li, X.H.; Yang, C.L.; Shen, H. Gentiotipicroside exerts convincing antitumor effects in human ovarian carcinoma cells (SKOV3) by inducing cell cycle arrest, mitochondrial mediated apoptosis and inhibition of cell migration. *J. BUON* 2019, 24, 280–284. [PubMed]

85. Sun, Y.; Lan, M.; Chen, X.; Dai, Y.; Zhao, X.; Wang, L.; Zhang, T.T.; Li, Y.B.; Zhu, J.L.; Zhang, X.M.; et al. Anti-invasion and anti-metastasis effects of Valjatrate E via reduction of matrix metalloproteinases expression and suppression of MAPK/ERK signaling pathway. *Biomed. Pharmacother.* 2018, 104, 817–824. [CrossRef] [PubMed]

86. Wang, H.; Huang, H.; Lv, J.; Jiang, N.; Li, Y.; Liu, X.; Zhao, H. Iridoid compounds from the aerial parts of *Sweria mussotii* Franch. with cytotoxic activity. *Nat. Prod. Res.* 2019, 1–6. [CrossRef]

87. Li, F.; Li, W.; Li, X. Geniposide attenuates inflammatory response by suppressing P2Y14 receptor and downstream ERK1/2 signaling pathway in oxygen and glucose deprivation-induced brain microvascular endothelial cells. *J. Ethnopharmacol.* 2016, 185, 77–86. [CrossRef]

88. Shoda, J.; Miura, T.; Utsunomiya, H. Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver. *Hepatology* 2004, 39, 167–178. [CrossRef]

89. Ding, S.T.; Liu, H.T.; Li, W.M. Protective effects of geniposide on human umbilical vein endothelial cell injury induced by H2O2 in vitro. *Chin. Pharmacol. Bull.* 2009, 25, 725–729.

90. Suzuki, Y.; Kondo, K.; Ikeda, Y. Antithrombotic Effect of Geniposide and Genipin in the Mouse Thrombosis Model. *Planta Med.* 2001, 67, 807–810. [CrossRef]

91. Villasenor, I.M. Bioactivities of iridoids. *Anti-Inflamm. Anti-Allergy Agents Med. Chem.* 2007, 6, 307–314. [CrossRef]

92. Lian, M.; Sun, Y.; Lin, Y. p-JAK2 plays a key role in capatal-induced protection against rat intestinal ischemia/reperfusion injury. *RSC Adv.* 2017, 7, 54369–54378. [CrossRef]

93. Jun-Sheng, T.; Bi-Yun, S.; Huan, X. 1H-NMR-Based Metabonomic Studies on the Anti-Depressant Effect of Genipin in the Chronic Unpredictable Mild Stress Rat Model. *PLoS ONE* 2013, 8, e75721.

94. Gutierrez, R.M.P.; Solis, R.V.; Baez, E.G. Effect on capillary permeability in rabbits of iridoids from *Buddleia scordioides*. *Phytother. Res.* 2006, 20, 542–545. [CrossRef] [PubMed]
95. Oh, S.R.; Lee, M.Y.; Ahn, K. Suppressive effect of verproside isolated from Pseudolysimachion longifolium on airway inflammation in a mouse model of allergic asthma. *Int. Immunopharmacol.* 2006, 6, 978–986. [CrossRef] [PubMed]

96. Zhong, H.; Chen, K.; Feng, M.Y.; Shao, W.; Wu, J.; Chen, K.; Liang, T.M.; Liu, C. Genipin alleviates high-fat diet-induced hyperlipidemia and hepatic lipid accumulation in mice via miR-142a-5p/SREBP1c axis. *FEBS J.* 2018, 285, 501–517. [CrossRef] [PubMed]

97. Li, Y.T.; Hu, W.J.; Han, G.H.; Lu, W.Q.; Jia, D.X.; Hu, M.; Wang, D. Involvement of bone morphogenetic protein–related pathways in the effect of aucubin on the promotion of osteoblast differentiation in MG63 cells. *Chem.-Biol. Interact.* 2018, 283, 51–58. [CrossRef]

98. Lee, J.H.; Lee, D.U.; Jeong, C.S. Central Inhibition of Arachnoid Ether Terpenoids. Master’s Thesis, Southwest Jiaotong University, Xi’an, China, May 2009.

99. Ma, W.W.; Tao, Y.; Wang, Y.Y.; Peng, I.F. *E. procumbens* extract and its constituents reduce the risks of gastritis and reverse gastric lesions in rats. *Food Chem. Toxicol.* 2009, 47, 1127–1131. [CrossRef]

100. Koo, H.J.; Lee, S.; Shin, K.H.; Kim, B.C.; Lim, C.J.; Park, E.H. Geniposide, an anti-angiogenic compound from *Gardenia jasminoides* Ellis ethanol extract and its constituents enhance the growth of angiogenesis-related genes. *Molecules* 2017, 23, 2856–2866. [CrossRef] [PubMed]

101. Wang, Y.; Dai, L.; Wu, H.; Zhang, Z.R.; Wang, W.Y.; Fu, J.; Deng, R.; Li, F.; Dai, X.J.; Zhang, X. Novel anti-inflammatory target of geniposide: Inhibiting Itgbeta1/Ras-Erk1/2 signal pathway via the miRNA-124a in rheumatoid arthritis syno-vial fibroblasts. *Int. Immunopharmacol.* 2018, 65, 284–294. [CrossRef]

102. Liu, Z.X.; Liu, C.T.; Liu, Q.B.; Ren, J.; Li, L.Z.; Huang, X.X.; Wang, Z.Z.; Song, S.J. Iridoid glycosides from the flowers buds of *Lonicerajaponica* and their nitric oxide production and α-glucosidase inhibitory activities. *J. Funct. Foods.* 2015, 18, 512–519. [CrossRef]

103. Toriizuka, K.; Kamiki, H.; Ohmura, N.Y.; Fujii, M.; Hori, Y.; Fukumura, M.; Hirai, Y.; Isoda, S.; Nemoto, Y.; Ida, Y. Anxiolytic effect of *Gardeniae Fructus*-extract containing active ingredient from Kamishoyosan (KSS), a Japanese traditional Kampo medicine. *Life Sci.* 2005, 77, 3010–3020. [CrossRef]

104. Chen, J.L.; Blanc, P.; Stoddart, C.A.; Bogan, M.; Rozhon, E.J.; Parkinson, N.; Ye, Z.J.; Cooper, R.; Balick, M.; Nanakorn, W.; et al. New Iridoids from the Medicinal Plant *Barleria, prionitis* with Potent Activity against Respiratory Syncytial Virus. *J. Nat. Prod.* 1998, 61, 1295–1297. [CrossRef]

105. Chen, L.; Yan, Y.; Zhang, L. Aucubin promotes angiogenesis via estrogen receptor beta in a mouse model of hindlimb ischemia. *J. Steroid Biochem. Mol. Biol.* 2017, 172, 149–159. [CrossRef] [PubMed]

106. Peng, J. Central Inhibition of Arachnoid Ether Terpenoids. Master’s Thesis, Southwest Jiaotong University, Xi’an, China, May 2009.

107. Shi, R.R.; Wang, J.; Yan, X.L.; Hu, J.H.; Gao, Z.P.; Jia, M.X.; Yu, X.; Wang, J. Study on the mechanism of arachnoid iridoids and terpenes on rats with irritable bowel syndrome. *J. Beijing Univ. Tradit. Chin. Med.* 2014, 37, 304–308.

108. Modaressi, M.; Delazar, A.; Nazemiyeh, H.; Fathi-Azad, F.; Smith, E.; Rahman, M.; Gibbons, S.; Nahar, L.; Sarker, S.D. Antibacterial Iridoid Glucosides from *Eremostachys laciniata* with Potent Activity against MDR Strains of *E. coli*. *Molecules* 2014, 19, 1259–1270. [CrossRef] [PubMed]

109. Cimanga, K.; Kambu, K.; Tona, L.; Hermans, N.; Apers, S.; Totté, J.; Pieters, L.; Vlietinck, A.J. Antiinflammatory Activity of Iridoids from *Gardenia jasminoides* Leaves. *Planta Med.* 2007, 72, 751–753. [CrossRef]

110. Pungitore, C.R.; Ayub, M.J.; Garcia, M. Iridoids as Allelochemicals and DNA Polymerase Inhibitors. *J. Nat. Prod.* 2004, 67, 357–361. [CrossRef]

111. Akhiha, T.; Seino, K.I.; Kaneko, E.; Watanabe, K.; Tochizawa, S.; Fukatsu, M.; Banno, N.; Metori, K.; Kimura, Y. Melanogenesis inhibitory activities of iridoid-, hemiterpene-, and fatty acid-glycosides from the fruits of *Gardenia jasminoides*. *Planta Med.* 1998, 64, 287–293. [CrossRef] [PubMed]

112. Yu, D.; Zhang, Y.; Guo, L.; Zhang, Q.; Zhu, H. Study on the Absorption Mechanism of Geniposide in the Chinese Formula Huang-Lian-Jie-Du-Tang in Rats. *AAPS PharmSciTech.* 2017, 18, 1382–1392. [CrossRef]

113. Qu, K.; Zhao, L.; Luo, X.; Zhang, C.; Hou, P.; Bi, K.; Chen, X. An LC-MS method for simultaneous determination of five iridoids from Zhi-zi-chi Decoction in rat brain microdialysates and tissue homogenates: Towards an in depth study for its antidepressive activity. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 2014, 965, 206–215. [CrossRef]
115. Zhang, X.; Wang, L.; Zheng, Z.; Pi, Z.; Liu, Z.; Song, F. Online microdialysis-ultra performance liquid chromatography-mass spectrometry method for comparative pharmacokinetic investigation on iridoids from *Gardenia jasminoides* Ellis in rats with different progressions of type 2 diabetic complications. *J. Pharm. Biomed. Anal.* 2017, 140, 146–154. [CrossRef]

116. Han, H.; Yang, L.; Xu, Y.; Ding, Y.; Bligh, S.W.; Zhang, T.; Wang, Z. Identification of metabolites of geniposide in rat urine using ultra-performance liquid chromatography combined with electrospray ionization quadrupole time-of-flight tandem mass spectrometry. * Rapid Commun. Mass Spectrom.* 2011, 25, 3339–3350. [CrossRef] [PubMed]

117. Wu, X.J.; Zhao, L.M. Serum Pharmacochemistry and Pharmacokinetics Study of Naoxuening Injection. *Tradit. Chin. Drug Res. Clin. Pharmacol.* 2008, 5, 52–55.

118. Ramakrishna, R.; Bhateria, M.; Singh, R.; Puttreve, S.K.; Bhatta, R.S. Plasma pharmacokinetics, bioavailability and tissue distribution of agnuside following peroral and intravenous administration in mice using liquid chromatography tandem mass spectrometry. *J. Sep. Sci.* 2016, 39, 154–164. [CrossRef]

119. Xu, G.L.; Li, H.L.; He, J.C.; Feng, E.F.; Shi, P.P.; Liu, Y.Q.; Liu, C.X. Comparative pharmacokinetics of swertiamarin in rats after oral administration of swertiamarin alone, Qing Ye Dan tablets and co-administration of swertiamarin and oleanolic acid. *J. Ethnopharmacol.* 2013, 149, 49–54. [CrossRef]

120. Wang, Z.G.; Wang, X.J.; Sun, H.; Chen, L.; Ma, C.M. Determination of novel nitrogen-containing metabolite after oral administration of swertiamarin to rats. *J. Asian Nat. Prod. Res.* 2012, 14, 176–181. [CrossRef]

121. Wang, Z.; Wang, S.; Sun, Y.; Wang, H.; Chen, G.; Wang, X.; Hattori, M.; Zhang, H. New analytical method for the study of the metabolism of gentiopicroside in rats after oral administration by LC-TOF-MS following picolinoyl derivatization. *J. Sep. Sci.* 2014, 37, 237–243. [CrossRef]

122. Wu, X.; Tang, S.; Jin, Y.; Zhang, Y.; Hattori, M.; Wang, X.; Zhang, H.; Wang, Z. New analytical method for the study of metabolism of swertiamarin in rats after oral administration by UPLC-TOF-MS following DNPH derivatization. *Biomed. Chromatogr.* 2015, 29, 1184–1189. [CrossRef]

123. Yang, Y.; Zhang, Z.; Li, S.; Ye, X.; Li, X.; He, K. Synergy effects of herb extracts: Pharmacokinetics and pharmacodynamic basis. *Fitoterapia* 2014, 92, 133–147. [CrossRef]

124. Badal, S.; Williams, S.A.; Huang, G.; Francis, S.; Vedantam, P.; Dunbar, O.; Jacobs, H.; Tzeng, T.J.; Gangemi, J.; Delgado, R. Cytochrome P450 1 enzyme inhibition and anticancer potential of chromene amides from *Amyris plumieri*. *Fitoterapia* 2011, 82, 230–236. [CrossRef]

125. Wu, Y.; Ai, Y.; Wang, F.; Ma, W.; Bian, Q.; Lee, D.Y.; Dai, R. Simultaneous determination of four secoiridoid and iridoid glycosides in rat plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a comparative pharmacokinetic study. *Biomed. Chromatogr.* 2016, 30, 97–104. [CrossRef]

126. Yang, T.M.; Liu, Y.X.; Fu, H.Y.; Lan, W.; Su, H.B.; Tang, H.B.; Yin, Q.B.; Li, H.D.; Wang, L.P.; Wu, H.L. Pharmacokinetic Analysis of Four Bioactive Iridoid and Secoiridoid Glycoside Components of *Radix Gentianae Macrophyllae* and Their Synergistic Excretion by HPLC-DAD Combined with Second-Order Calibration. *Nat. Prod. Bioprospect.* 2017, 7, 445–459. [CrossRef]

127. Zhu, J.; Xue, B.; Ma, B.; Zhang, Q.; Liu, M.; Liu, L.; Yao, D.; Qi, H.; Wang, Y.; Ying, H.; et al. A pre-clinical pharmacokinetic study in rats of three naturally occurring iridoid glycosides, Picroside-I, II and III, using a validated simultaneous HPLC-MS/MS assay. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 2015, 993–994, 47–59. [CrossRef]

128. Zahiruddin, S.; Khan, W.; Nehra, R.; Alam, M.J.; Mallick, M.N.; Parveen, R.; Ahmad, S. Pharmacokinetics and comparative metabolic profiling of iridoid enriched fraction of *Picrorhiza kurroa*—An Ayurvedic Herb. *J. Ethnopharmacol.* 2017, 197, 157–164. [CrossRef]

129. Hou, Y.C.; Tsai, S.Y.; Lai, P.Y.; Chao, P.D.L. Metabolism and pharmacokinetics of genipin and geniposide in rats. *Food Chem. Toxicol.* 2008, 46, 2764–2769. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).